Acrylic Acid Ethyl Ester

Acrylic Acid Ethyl Ester

SCHEMBL239185

C=C(C)C(=O)OCCN(C)C.C=CC(=O)OCC

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 2/20 0.47
TSHR P16473 10/20 0.42
HPGD P15428 1/20 0.41
CHRM2 P08172 1/20 0.40
CHRM4 P08173 1/20 0.40
CHRM5 P08912 1/20 0.40
CHRM1 P11229 1/20 0.40
CHRNB2 P17787 1/20 0.40
CHRM3 P20309 1/20 0.40
CHRNA4 P43681 1/20 0.40
ALDH1A1 P00352 5/20 0.37
TP53 P04637 2/20 0.37
HIF1A Q16665 2/20 0.37
CYP3A4 P08684 1/20 0.37
HSD17B10 Q99714 1/20 0.37
DNM1 Q05193 1/20 0.36
NPSR1 Q6W5P4 1/20 0.35
MAPT P10636 1/20 0.35
BCHE P06276 1/20 0.33
HCAR2 Q8TDS4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acrylic Acid Ethyl Ester SCHEMBL7542173 0.96 THRB (0.44) THRBTSHRHPGDCHRM2CHRM4
Acrylic Acid Ethyl Ester SCHEMBL6761428 0.94 THRB (0.43) THRBTSHRHPGDCHRM2CHRM4
SCHEMBL1538397 0.92 TSHR (0.44) THRBTSHRHPGDCHRM2CHRM4
Acrylic Acid Ethyl Ester SCHEMBL27698745 0.90 ALDH1A1 (0.42) THRBTSHRHPGDCHRM2CHRM4
Methacrylic Acid SCHEMBL28076204 0.88 TSHR (0.41) THRBTSHRHPGDCHRM2CHRM4
SCHEMBL10597742 0.87 THRB (0.56) THRBTSHRCHRM2CHRM4CHRM5
Acrylic Acid Ethyl Ester SCHEMBL17044687 0.87 TSHR (0.53) THRBTSHRHPGDCHRM2CHRM4
SCHEMBL5965838 0.87 TSHR (0.41) THRBTSHRHPGDCHRM2CHRM4
SCHEMBL5998966 0.87 TSHR (0.61) THRBTSHRHPGDCHRM2CHRM4
SCHEMBL22441621 0.87 TSHR (0.41) THRBTSHRHPGDCHRM2CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114681324-B Double-release dosage form capsule and preparation method, device and system thereof 盖尔凯普科技有限公司 2024-05-03 CN disclosed
EP-3167936-B1 COSMETIC METHOD FOR TREATING HUMAN PERSPIRATION USING PARTICLES OF AN EXPANDED AMORPHOUS MINERAL MATERIAL; COMPOSITIONS OREAL (FR) 2023-06-07 EP disclosed
CN-108969406-B Cosmetic use of monounsaturated fatty acids or one of their salts and/or one of their esters or amides as deodorant active agent 莱雅公司 2022-05-27 CN disclosed
US-11266583-B2 Cosmetic method for treating human perspiration using particles of an expanded amorphous mineral material; compositions L'OREAL (FR) 2022-03-08 US disclosed
EP-2642974-B1 PROCESS FOR TREATING PERSPIRATION USING A CARBONYL COMPOUND CAPABLE OF REACTING VIA THE MAILLARD REACTION OREAL (FR) 2021-05-19 EP disclosed
US-10966913-B2 Cosmetic use of spiculisporic acid as a deodorant active agent L'OREAL (FR) 2021-04-06 US disclosed
EP-2925413-B1 COSMETIC WATER-IN-OIL EMULSION IN AEROSOL FORM, COMPRISING AT LEAST ONE VINYL POLYMER CONTAINING AT LEAST ONE CARBOSILOXANE DENDRIMER-BASED UNIT, AT LEAST ONE OLEFIN COPOLYMER AND AT LEAST ONE ANTIPERSPIRANT ACTIVE AGENT OREAL (FR) 2019-07-03 EP disclosed
US-10307365-B2 Cosmetic use of a geraniol-rich essential oil of Satureja montana as deodorant active agent L'OREAL (FR) 2019-06-04 US disclosed
EP-2906183-B1 COSMETIC USE OF A MONOUNSATURATED FATTY ACID OR ONE OF ITS SALTS AND/OR OF ITS ESTERS OR AMIDES AS DEODORANT ACTIVE AGENT OREAL (FR) 2019-03-20 EP disclosed
EP-2988827-B1 COSMETIC USE OF A GERANIOL-RICH ESSENTIAL OIL OF SATUREJA MONTANA AS DEODORANT ACTIVE AGENT OREAL (FR) 2019-01-30 EP disclosed
EP-2358444-A1 COSMETIC METHOD FOR TREATING HUMAN PERSPIRATION USING PARTICLES OF AN EXPANDED AMORPHOUS MINERAL MATERIAL; COMPOSITIONS L'Oréal (FR) 2011-08-24 EP disclosed
WO-2011073438-A2 COSMETIC METHOD FOR TREATING BODY ODOURS USING A BACTERIOCIN BASED COMPOSITION L'OREAL (FR) 2011-06-23 WO disclosed
WO-2011073440-A2 DEODORANT COMPOSITION BASED ON ANTIMICROBIAL PEPTIDES AND METHOD FOR TREATING BODY ODOUR L'OREAL (FR) 2011-06-23 WO disclosed
WO-2010054921-A1 COSMETIC METHOD FOR TREATING HUMAN PERSPIRATION USING PARTICLES OF AN EXPANDED AMORPHOUS MINERAL MATERIAL; COMPOSITIONS L'OREAL (FR) 2010-05-20 WO disclosed
US-20070148113-A1 Antiperspirant compositions comprising at least one dispersion of cationic colloidal silica particles, antiperspirant product, and cosmetic process for treating perspiration L'OREAL S.A. (FR) 2007-06-28 US disclosed
EP-1663515-A4 POROUS CERAMIC FILTERS WITH CATALYST COATINGS CORNING INC (US) 2007-04-04 EP disclosed
EP-1663515-A2 POROUS CERAMIC FILTERS WITH CATALYST COATINGS CORNING INCORPORATED (US) 2006-06-07 EP disclosed
WO-2005018790-A2 POROUS CERAMIC FILTERS WITH CATALYST COATINGS CORNING INCORPORATED (US) 2005-03-03 WO disclosed
US-20050037147-A1 Porous ceramic filters with catalyst coatings CORNING INCORPORATED 2005-02-17 US disclosed
EP-0003431-A1 Production of carboxylic acid anhydrides and catalysts therefor IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1979-08-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10966913-B2 Cosmetic use of spiculisporic acid as a deodorant active agent DPM1, KRT18, TYR THRB 2736/4885TSHR 2556/4885HPGD 1252/4885
US-10307365-B2 Cosmetic use of a geraniol-rich essential oil of Satureja montana as deodorant active agent CUTA, DAGLA, KRT18 THRB 395/4885TSHR 1965/4885HPGD 2007/4885
US-11266583-B2 Cosmetic method for treating human perspiration using particles of an expanded amorphous mineral material; compositions CUTA, FABP4, SOST THRB 3114/4885TSHR 2327/4885HPGD 3067/4885
US-20070148113-A1 Antiperspirant compositions comprising at least one dispersion of cationic colloidal silica particles, antiperspirant product, and cosmetic process for treating perspiration TRPA1, CUTA, PIEZO1 THRB 4635/4885TSHR 2474/4885HPGD 4463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.